99768-67-9 Usage
Uses
Used in Pharmaceutical Synthesis:
5-Nitro-4-hydroxyquinazoline is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Dye Production:
In the chemical industry, 5-Nitro-4-hydroxyquinazoline serves as an intermediate in the production of dyes. Its ability to form colored compounds makes it a valuable component in the creation of a range of dyes used in different applications.
Used in Antibacterial Applications:
5-Nitro-4-hydroxyquinazoline has demonstrated antibacterial properties, making it a potential candidate for the development of new antibiotics. Its ability to inhibit bacterial growth could be harnessed to create treatments for various bacterial infections.
Used in Antitumor Applications:
5-Nitro-4-hydroxyquinazoline has also shown antitumor activities, indicating its potential use in cancer research and drug development. 5-Nitro-4-hydroxyquinazoline could be further studied and optimized to target specific types of cancer cells, offering a new avenue for cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 99768-67-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,9,7,6 and 8 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 99768-67:
(7*9)+(6*9)+(5*7)+(4*6)+(3*8)+(2*6)+(1*7)=219
219 % 10 = 9
So 99768-67-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H5N3O3/c12-8-7-5(9-4-10-8)2-1-3-6(7)11(13)14/h1-4H,(H,9,10,12)
99768-67-9Relevant academic research and scientific papers
Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account
Wu, Frank,Büttner, Frank H.,Chen, Rhonda,Hickey, Eugene,Jakes, Scott,Kaplita, Paul,Kashem, Mohammed A.,Kerr, Steven,Kugler, Stanley,Paw, Zofia,Prokopowicz, Anthony,Shih, Cheng-Kon,Snow, Roger,Young, Erick,Cywin, Charles L.
scheme or table, p. 3235 - 3239 (2010/08/22)
Two closely related scaffolds were identified through an uHTS campaign as desirable starting points for the development of Rho-Kinase (ROCK) inhibitors. Here, we describe our hit-to-lead evaluation process which culminated in the rapid discovery of potent leads such as 22 which successfully demonstrated an early in vivo proof of concept for anti-hypertensive activity.
